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Introduction
Several studies have sought to evaluate the screening accuracy of HPV detection tests, after the recognition that infection by high oncogenic risk types is required for the development of cervical cancer.
1,2 A meta-analysis comparing the HPV detection test with the cytological examination 3 found that the HPV test was more sensitive in detecting cervical intraepithelial neoplasia grade 2 or higher (CIN2þ). The specificity, however, was lower, even in women over 30 years old, where HPV infection tends to be less frequent.
Recently, a systematic review of randomized studies that evaluated the HPV detection test in the screening of cervical cancer was performed. 4 Six studies were included in the analysis, although there were differences regarding the type of cytological exam and HPV detection used, eligibility criterion, and forwarding for colposcopy. Despite the methodological differences, the authors concluded that, after two rounds of screening, the HPV test was more sensitive than the cytological examination for the detection of cervical intraepithelial neoplasia grade 3 or higher, but only when a positive HPV test was used as a criterion for immediate referral to colposcopy, even with normal cytological examination. None of the studies, however, resembled the followup strategy recommended by the Brazilian program for the prevention of cervical cancer.
5
The main barrier to the success of screening with conventional cytology is the difficulty of access to carry out examinations and treatment. This barrier, however, generally does not occur for women participating in clinical studies. In a study conducted in India, 6 for example, the control group received only guidance about the places that performed the Pap smear, without guaranteeing it. After eight years of follow-up, the authors observed that screening with the HPV test provided a statistically significant protection against death by cervical cancer and diagnosis of the disease with advanced staging. The results, however, were similar when compared with the intervention group submitted only to the Pap test. The objective of this study was to compare the predictive capacity of the HPV test with the Pap test in detecting precursor cervical cancer lesions, in a population of users of the Unified Health System (SUS).
Methods

Study Design and Sample Population
This was a retrospective cohort study, using the existing records of the results of cytological, colposcopic, and histopathological tests from 2002 to 2006. These data were extracted from the Cervix Cancer Information System (Sistema de Informação do Câncer do Colo do Útero -SISCOLO) of the State of Rio de Janeiro and from the medical records of women participating in the study in the health units concerning diagnostic confirmation and treatment. Additionally, death data were obtained from the Mortality Information System (SIM) of the State of Rio de Janeiro. In all, 2,032 women were eligible for the study by presenting a satisfactory Pap test and HPV test in a prior examination. 7 The samples were analyzed by the Integrated Technology Service in Cytopathology (Serviço Integrado de Tecnologia em Citopatologia -SITEC) of the Brazilian National Cancer Institute (INCA). Women for whom at least one exam (Pap, colposcopy, or histopathology) was not present in the sources consulted during the follow-up period were excluded.
Resumo
Variables Analyzed
The The HPV test used was a second generation hybrid capture method for a cervical-vaginal smear. The results were categorized as positive when the evidence used for high-risk oncogenic types was equal to or higher than the positive control, and negative for the rest.
Age was classified into three categories based on the date of enrollment in the study: 25 to 34 years, 35 to 49 years, and 50 to 59 years.
The outcome of interest was a diagnosis of Cervical Intraepithelial Neoplasia grade 2 or higher (CIN2þ) in the histopathological evaluation.
All women included in the study were observed from the date of collection for the Pap and HPV tests, which occurred at the same time. We considered the first diagnosis of CIN2þ in the histopathological evaluation as the criterion of failure. The observation was censored at the date of the last test (Pap test, colposcopy, or histopathology) performed or after 36 months of follow-up.
To evaluate the possibility of selective loss, women who did not complete the follow-up were compared with those with complete follow-up in relation to socioeconomic and demographic characteristics, as well as the results of examinations performed at enrollment (Pap and HPV).
To evaluate the predictive capacity of each test, progression curves for CIN2þ were constructed for the period evaluated, using the Kaplan-Meier method. The curves were stratified considering the results of examinations performed and the age groups at enrollment. The log-rank test was used to compare the curves for each stratum during the follow-up period, and a difference was considered significant when the p value was less than 0.05. The sensitivity, specificity, positive and negative predictive value, and the positive (LRþ) and negative likelihood ratio (LR-), which describes the performance of the test summarizing the information of sensitivity and specificity, 9 were also calculated for the follow-up period. The Chi-square test ( 2 ) was used to compare the proportions evaluated, considering the statistically significant difference when p value was lower than 0.05. We performed the analyses using the R statistical program (version 2.5.1). The research was approved by the Research Ethics Committee of the Brazilian National Cancer Institute (registration number 074/06).
Results
A total of 1,440 women (70.9%) had attended at least one exam in the follow-up period evaluated. The study population was similar to the eligible population (2,032 women) regarding the municipality of residence, age group, family income, educational level, and the results of initial tests (p > 0.05). However, a lower proportion of women with both exams negative (80.2% versus 75.1%; p < 0.001) was included in the study (data not shown).
Information was obtained in 53.9% of the population studied until the end of the follow-up period (36 months), and 76.8% for at least 18 months. ►Table 1 presents the socioeconomic and demographic characteristics and the results of initial exams of the study population (1,440) and those with complete follow-up (776). Selective loss was not observed in relation to the variables assessed (p > 0.05).
Among the women with incomplete follow-up (664), 273 (41.1%) presented two consecutive negative Pap tests, with a minimum interval of twelve months. In accordance with the recommendations of the Brazilian program, 5 these women should be examined again only after three years, that is, after the conclusion of the study. Additionally, 184 (27.7%) women presented with a negative colposcopic or histopathological evaluation in the last exam performed and, in 97 (14.6%), the last Pap test was negative. During the follow-up period, four women died, three of them from causes not related to cervical cancer and with a negative initial Pap test, and one by ill-defined and not specified causes who had presented with a high-grade lesion in the initial Pap test and CIN1 in the histopathological evaluation. All presented with a negative HPV test at enrollment.
Fifty-three women were identified with CIN2þ in the follow up period, and the majority (67.9%) presented with altered Pap and HPV tests at enrollment. 20.8% of the cases had only an altered HPV test, including a single case of adenocarcinoma diagnosed during the period. Three cases with a diagnosis of CIN2, however, had both tests (Pap test and HPV) normal at enrollment (►Table 2).
The curves of progression for CIN2þ stratified by age group were overlapped (p ¼ 0.83), indicating no significant difference in the population studied, during the follow-up period evaluated (data not shown outcome of the initial tests (►Fig. 1), in turn, point to differences in the predictive capacity for CIN2þ according to the results of the tests (p < 0.001), being expressively higher when both test results were altered, followed by having only the HPV test positive.
Screening with the HPV test revealed a higher sensitivity than the Pap test (88.7% and 73.6%, respectively; p < 0.05) and a similar specificity (86.0 and 88.1, respectively; p ¼ 0.10). Screening with the tests combined presented similar sensitivity (94.3%, p ¼ 0.49) and lower specificity With regard to the positive and negative likelihood ratio of the tests evaluated, the performance of the HPV test was similar to the Pap test, whose likelihood of detecting CIN2þ among women with an altered test was about 6-fold higher than in the total population. However, the likelihood of detecting CIN2þ among women with both tests negative (LR-¼ 0.07; IC95%: 0.02-0.22) or with only the HPV test negative (LR-¼ 0.13; IC 95%: 0.06-0.28) was very low, which was not the case for women with only the negative Pap smear test (LR-¼ 0.30; CI 95%: 0.13-0.47).
Discussion
In this study, only women who submitted to at least one exam in the follow-up period were included, resulting in a lower proportion of women with both initial exams negative than the reference population. Consequently, the population included probably had a greater likelihood of detecting CIN2þ, suggesting that the estimates obtained may be overestimated. However, as there was no selective loss of followup, we expect the estimates to be comparable between the tests evaluated.
Screening with the HPV test presented a similar performance to the Pap test for detection of CIN2þ, with a positive likelihood ratio of around 6. However, the sensitivity of the HPV test was higher and having a negative HPV test provided a smaller likelihood (LR-) of detection of CIN2þ than having a negative Pap test, at three years of follow-up. The use of these tests combined did not present a better performance than the HPV test alone.
In a randomized study conducted in Sweden, 10 the researchers used the Pap test and PCR for identification of HPV in the two arms of the study, but with the result of the PCR revealed only in the intervention group. However, after three years of follow-up, it was necessary to apply the same referral protocol for diagnostic confirmation in the control group because the proportion of HPV positive women with diagnosis of CIN2þ in the intervention group was greater than that expected. In contrast, in a non-randomized study conducted in the United States, 11 with ten-year follow-up, the authors observed initially a higher risk of detection of CIN3þ associated with positivity on the Pap test compared with positivity on the HPV test. This occurred particularly in the first nine months, but the differences between the estimates decreased over the follow-up. In a study conducted in Italy, 14 screening with the HPV test was more sensitive in detecting CIN2þ, in particular for younger women (< 35 years). The authors concluded that these findings could represent an over-diagnosis of lesions that would regress. In the present study, around 20% of women with CIN2þ had positive HPV and negative Pap results, half of them with more than 34 years of age. Therefore, it is possible that a portion of these lesions could progress, and women with greater difficulty of access to screening and health services could be diagnosed later, implying a worse clinical outcome. In this study, the difference in sensitivity of the HPV and Pap tests (88.7 and 73.6%, respectively) was significant, although the Pap test performed upon enrollment was analyzed in a reference laboratory (SITEC) with proven quality, which increases the probability of approaching the maximum sensitivity expected for this test. However, this difference could be even higher if all Pap tests were performed in different laboratories given that sensitivity values below 31% have already been described in the country.
15-17
Additionally, the Pap test presents a low capacity to detect adenocarcinomas which represent around 10% of cervical cancers.
18
Although the results suggest that the HPV test can have an advantage compared with the reference test used in the country, its application depends on multiple logistic and technical issues for which the diagnostic capacity of most municipalities is still not ready. The incorporation of the test in the long term can have a cost benefit, but the cost of the initial deployment is high because the public laboratories and contractors of SUS need to be equipped to perform the test.
One can conclude that the HPV test should be considered in the primary screening of cervical cancer at least once in life, in particular for women with greater difficulty of access to health services. However, additional studies should be conducted in a routine context and with a greater follow-up period to evaluate its efficacy in the prevention of cervical cancer, and the consequent cost of the process. One should also assess the technical, welfare, and social implications of the diagnosis of HPV infection, a sexually transmissible disease, in the screening of cervical cancer.
